BDNF and Parkinson disease: The overarching goal of the present study is to determine the extent by which pharmacologically elevating both neuroprotective PKA signaling and BDNF levels in the midbrain via intranasal delivery of Forskolin and Noopept can reverse PD pathology in symptomatic Parkinsonian rats (PINK1 knockout) [63,64].